Veldwijk, Jorien http://orcid.org/0000-0003-4822-5068
DiSantostefano, Rachael Lynn
Janssen, Ellen
Simons, Gwenda
Englbrecht, Matthias
Schölin Bywall, Karin
Radawski, Christine
Raza, Karim
Hauber, Brett
Falahee, Marie
Funding for this research was provided by:
Innovative Medicines Initiative (115966)
Article History
Accepted: 19 July 2023
First Online: 30 August 2023
Declarations
:
: This study formed part of the Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project. The PREFER project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 115966. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. Karim Raza is supported by the National Institute for Health and Care Research Birmingham Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the National Institute for Health and Care Research or the Department of Health and Social Care. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
: Rachael DiSantostefano and Ellen Janssen are employed by Janssen Research and Development, LLC and are stockholders in Johnson & Johnson. Brett Hauber is employed by Pfizer, Inc. and holds stock or stock options in Pfizer. Jorien Veldwijk, Gwenda Simons, Karin Schölin Bywall, and Marie Falahee have no conflicts of interest that are directly relevant to the content of this article. Karim Raza declared personal fees from Abbvie and Sanofi, and grant/research support from Bristol Myers Squibb. Matthias Englbrecht declares personal fees from AbbVie, Chugai, Eli Lilly, Novartis, Roche, Sanofi, and Mundipharma and grant/research support from Roche and Chugai.
: This study was approved by the London-Hampstead Research Ethics Committee (19/LO/0407).
: Not applicable.
: Not applicable.
: Data are available upon reasonable request to the authors.
: Not applicable.
: JV, RLD, and KR acquired funding. All authors were included in the final selection of methods for the study. GS, ME, KR, and MF led the clinical elements of the study including the attribute selection and contact with the patient research partner(s). JV, RLD, EJ, KSB, CR, and BH led the design for both methods. JV, GS, MF, and KR led survey programming and respondent recruitment. JV, EJ, and BH conducted the analyses. JV, RLD, EJ, and MF drafted the manuscript. All authors reviewed and approved the final manuscript.